PDF herunterladen
CC BY 4.0 · TH Open 2018; 02(04): e357-e368
DOI: 10.1055/s-0038-1673389
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment

Thomas O. Bergmeijer
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Mathijs van Oevelen
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Paul W. A. Janssen
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Thea C. Godschalk
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Robert A. Lichtveld
2   Regional Ambulance Service Utrecht (RAVU), Bilthoven, The Netherlands
,
Johannes C. Kelder
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Michiel Voskuil
3   Division of Heart and Lungs, Department of Cardiology, UMC Utrecht, The Netherlands
,
Arend Mosterd
4   Department of Cardiology, Meander Medical Center, Amersfoort, The Netherlands
,
Gilles Montalescot
5   ACTION Study Group, UPMC Sorbonne Universités, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
,
Jurriën M. ten Berg
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
› Institutsangaben
Funding No external funding was received for this study.
Weitere Informationen

Publikationsverlauf

09. Februar 2018

22. August 2018

Publikationsdatum:
11. Oktober 2018 (online)

Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Objectives The objective of this registry was to study the safety of prehospital initiation of ticagrelor compared with clopidogrel.

Background Ticagrelor has replaced clopidogrel in many hospitals as the routinely used antiplatelet drug in patients with ST-segment elevation myocardial infarction (STEMI). Nevertheless, in the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor was associated with an increase in non-CABG (non–coronary artery bypass grafting)-related major bleeding. Data comparing the safety of ticagrelor and clopidogrel after prehospital initiation of treatment are not available.

Methods A retrospective, multicenter registry was performed. Selection criteria were the administration of a prehospital loading dose of ticagrelor or clopidogrel according to the ambulance STEMI treatment protocol and the presentation to a percutaneous coronary intervention–capable hospital in our region between January 2011 and December 2012. Follow-up was performed using the electronic patient files for the time period between the antiplatelet loading dose and hospital discharge. The data were analyzed using a primary bleeding end point (any bleeding) and a secondary thrombotic end point (all-cause mortality, spontaneous myocardial infarction, definite stent thrombosis, stroke, or transient ischemic attack).

Results Data of 304 clopidogrel-treated and 309 ticagrelor-treated patients were available for analysis. No significant difference in bleeding rate was observed between both groups, using univariate (17.8 vs. 20.1%; p = 0.47; odds ratio, 1.16 [95% confidence interval, 0.78–1.74]) and multivariate (p = 0.42) analysis. Also for the secondary thrombotic end point (6.3 vs. 4.9%, p = 0.45), no significant differences were observed.

Conclusion In this real-world registry, no significant differences in bleeding or thrombotic event rate were found between ticagrelor and clopidogrel after prehospital initiation of treatment.

Keywords

myocardial infarction - ticagrelor - clopidogrel - prehospital emergency care - hemorrhage
 

  • References

  • 1 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357 (24) 2482-2494
    CrossrefPubMedSuche in Google Scholar
  • 2 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8 (11) 1227-1234
    CrossrefPubMedSuche in Google Scholar
  • 3 Vlaar PJ, Svilaas T, Damman K. , et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review. Circulation 2008; 118 (18) 1828-1836
    CrossrefPubMedSuche in Google Scholar
  • 4 Mehta SR, Yusuf S, Peters RJ. , et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527-533
    CrossrefPubMedSuche in Google Scholar
  • 5 Sabatine MS, Cannon CP, Gibson CM. , et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352 (12) 1179-1189
    CrossrefPubMedSuche in Google Scholar
  • 6 Chen ZM, Jiang LX, Chen YP. , et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366 (9497): 1607-1621
    CrossrefPubMedSuche in Google Scholar
  • 7 Montalescot G, van 't Hof AW, Lapostolle F. , et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371 (11) 1016-1027
    CrossrefPubMedSuche in Google Scholar
  • 8 van Werkum JW, Heestermans AA, de Korte FI. , et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009; 119 (06) 828-834
    CrossrefPubMedSuche in Google Scholar
  • 9 Grimfjärd P, Erlinge D, Koul S. , et al. Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report. Am Heart J 2016; 176: 78-82
    CrossrefPubMedSuche in Google Scholar
  • 10 Ibanez B, James S, Agewall S. , et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedSuche in Google Scholar
  • 11 O'Gara PT, Kushner FG, Ascheim DD. , et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127 (04) e362-e425
    PubMedSuche in Google Scholar
  • 12 Wiviott SD, Braunwald E, McCabe CH. , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
    CrossrefPubMedSuche in Google Scholar
  • 13 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
    CrossrefPubMedSuche in Google Scholar
  • 14 Gurbel PA, Bliden KP, Butler K. , et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120 (25) 2577-2585
    CrossrefPubMedSuche in Google Scholar
  • 15 Umemura K, Iwaki T. The pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy japanese volunteers. Clin Pharmacol Drug Dev 2016; 5 (06) 480-487
    CrossrefPubMedSuche in Google Scholar
  • 16 Beigel R, Fefer P, Rosenberg N. , et al. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. Am J Cardiol 2013; 112 (10) 1551-1556
    CrossrefPubMedSuche in Google Scholar
  • 17 Bergmeijer TO, Godschalk TC, Janssen PWA. , et al. How long does it take for clopidogrel and ticagrelor to inhibit platelets in patients undergoing primary percutaneous coronary intervention? A detailed pharmacodynamic analysis: Time course of platelet reactivity in STEMI (TOPS). Semin Thromb Hemost 2017; 43 (04) 439-446
    Thieme ConnectPubMedSuche in Google Scholar
  • 18 Campo G, Valgimigli M, Gemmati D. , et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48 (11) 2178-2185
    CrossrefPubMedSuche in Google Scholar
  • 19 Heestermans AA, van Werkum JW, Taubert D. , et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008; 122 (06) 776-781
    CrossrefPubMedSuche in Google Scholar
  • 20 Steg PG, James SK, Atar D. , et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
    CrossrefPubMedSuche in Google Scholar
  • 21 Mehran R, Lansky AJ, Witzenbichler B. , et al; HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374 (9696): 1149-1159
    CrossrefPubMedSuche in Google Scholar
  • 22 Van't Hof AW, Ten Berg J, Heestermans T. , et al; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372 (9638): 537-546
    CrossrefPubMedSuche in Google Scholar
  • 23 Mehran R, Rao SV, Bhatt DL. , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedSuche in Google Scholar
  • 24 Thygesen K, Alpert JS, Jaffe AS. , et al; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60 (16) 1581-1598
    CrossrefPubMedSuche in Google Scholar
  • 25 Cutlip DE, Windecker S, Mehran R. , et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115 (17) 2344-2351
    CrossrefPubMedSuche in Google Scholar
  • 26 Steg PG, van 't Hof A, Hamm CW. , et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369 (23) 2207-2217
    CrossrefPubMedSuche in Google Scholar
  • 27 Silvain J, Storey RF, Cayla G. , et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2016; 116 (02) 369-378
    Thieme ConnectPubMedSuche in Google Scholar
  • 28 Dörler J, Edlinger M, Alber HF. , et al; Austrian Acute PCI Investigators. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011; 32 (23) 2954-2961
    CrossrefPubMedSuche in Google Scholar
  • 29 Koul S, Smith JG, Scherstén F, James S, Lagerqvist B, Erlinge D. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2011; 32 (23) 2989-2997
    CrossrefPubMedSuche in Google Scholar
  • 30 Zeymer U, Arntz HR, Mark B. , et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012; 101 (04) 305-312
    CrossrefPubMedSuche in Google Scholar
  • 31 Bellemain-Appaix A, Bégué C, Bhatt DL. , et al. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. EuroIntervention 2018; 14 (01) 78-85
    CrossrefPubMedSuche in Google Scholar
  • 32 Clemmensen P, Grieco N, Ince H. , et al; MULTIPRAC study investigators. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care 2015; 4 (03) 220-229
    CrossrefPubMedSuche in Google Scholar
  • 33 De Backer O, Ratcovich H, Biasco L. , et al. Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study. Thromb Haemost 2015; 114 (03) 623-631
    Thieme ConnectPubMedSuche in Google Scholar
  • 34 Cayla G, Lapostolle F, Ecollan P. , et al; ACTION study group. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. Int J Cardiol 2017; 244: 49-53
    CrossrefPubMedSuche in Google Scholar
  • 35 McEvoy JW, Ibrahim K, Kickler TS. , et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: The PACIFY randomized clinical trial (platelet aggregation with ticagrelor inhibition and fentanyl). Circulation 2018; 137 (03) 307-309
    CrossrefPubMedSuche in Google Scholar
  • 36 Hobl EL, Stimpfl T, Ebner J. , et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63 (07) 630-635
    CrossrefPubMedSuche in Google Scholar
  • 37 Parodi G, Bellandi B, Xanthopoulou I. , et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014; 8 (01) e001593
    CrossrefPubMedSuche in Google Scholar
  • 38 Fournier N, Toesca R, Bessereau J. , et al. Ticagrelor or prasugrel for pre-hospital protocols in STEMI?. Int J Cardiol 2013; 168 (04) 4566-4567
    CrossrefPubMedSuche in Google Scholar